Experimental drug shows promise in Alzheimer’s mice
By Alice Tuohy | Wednesday 02 January 2019
Cell Reports: Rescue of Transgenic Alzheimer’s Pathophysiology by Polymeric Cellular Prion Protein Antagonists
Researchers from Yale University in the US have identified an experimental drug that can block a crucial step in the Alzheimer’s disease process, showing it to improve nerve cell connections and memory function in mice with features of the disease. The study is published today (2 January 2019) in Cell Reports.
Dr David Reynolds, Chief Scientific Officer at Alzheimer’s Research UK, said:
“Stopping or slowing processes that drive damage in Alzheimer’s disease is a key area of focus for researchers, and this study identifies a new experimental drug that can do this in mice. This approach blocks the interaction between amyloid and another Alzheimer’s protein, preventing a key early step in the destructive cascade in the disease.”
“The researchers showed that this experimental drug is able to improve memory symptoms and restore vital nerve cell connections in mice bred to have features of Alzheimer’s. These promising early results will need to be reproduced in further experiments that also establish the drug’s safety profile, before it can enter clinical trials to see whether it is effective in people with Alzheimer’s disease.”
“With no new drug treatment for dementia in over 15 years, promising early findings like this serve as a positive reminder that research is making progress towards breakthroughs that will change lives.”